PAREXEL Continues Expansion of Site Alliance Network
Global network accelerates patient recruitment and clinical trial start-up times
PAREXEL announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients’ clinical trials worldwide.
To address challenges in patient recruitment, PAREXEL developed its Site Alliance network, currently consisting of more than 180 members plus several SMOs, together providing access to approximately 6,000 investigators worldwide. The SMOs alone have a combined database of 7.5 million patients in more than 25 countries. The network is currently in all the major regions where PAREXEL runs clinical trials, and is expanding to 200 sites. The network’s size and scope fosters strategic collaboration between PAREXEL and sites on behalf of clients and ensures quality across multiple sites.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
